Nisa Investment Advisors
KNTE

Nisa Investment Advisors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Nisa Investment Advisors’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-416
Closed -$1.26K – 2861
2023
Q2 		$1.26K Sell
416
-28
-6% -$108 ﹤0.01% 2403
2023
Q1 		$3K Sell
444
-1,872
-81% -$11.4K ﹤0.01% 2305
2022
Q4 		$14K Hold
2,316
– – ﹤0.01% 2136
2022
Q3 		$20K Hold
2,316
– – ﹤0.01% 2060
2022
Q2 		$29K Buy
2,316
+416
+22% +$3.87K ﹤0.01% 1933
2022
Q1 		$21K Buy
+1,900
New +$20.9K ﹤0.01% 2044

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Nisa Investment Advisors's KNTE Position: Q3 2023 in Review

Nisa Investment Advisors sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 416 shares — an estimated $1.26K sold.

Nisa Investment Advisors first reported a position in KNTE in Q1 2022 and held it in 6 quarters. The position peaked at $29K in Q2 2022. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

  • Nisa Investment Advisors reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Nisa Investment Advisors sold 416 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $1.26K.
  • Nisa Investment Advisors first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2022 and held it in 6 quarters.
  • Nisa Investment Advisors's Kinnate Biopharma Inc. Common Stock position peaked at $29K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on Nisa Investment Advisors's 13F filing for Q3 2023, filed 2 Nov 2023.